Speakers

Dr. David Weinstock is the Lavine Family Professor at Dana-Farber Cancer Institute and a Professor of Medicine and Pediatrics at Harvard Medical School. He completed fellowship training in Medical Oncology and Infectious Diseases at Memorial Sloan-Kettering Cancer Center. He joined the staff of Dana-Farber Cancer Institute and Brigham and Women’s Hospital in 2008, where he is a medical oncologist and directs a translational research program focused on novel therapeutics for lymphoid malignancies. He developed the Public Repository of Xenografts (http://www.PRoXe.org), which shares patient-derived xenograft models around the world. He is a National Cancer Institute Outstanding Investigator and leads the Leukemia Program for the Dana-Farber/Harvard Cancer Center. He has mentored several junior scientists who now lead their own scientific groups at Harvard and elsewhere.  In January 2022, he transitioned to become the Vice President of Discovery Oncology at MSD.

Dr Deepti H Radia, Haematology Consultant, Guy’s & St Thomas’ Hospitals NHS Foundation Trust, London.UK.
Deepti Radia, MRCPI, FRCPath, MSc Med Ed.

Deepti has been in her consultant post at Guys and St Thomas Hospitals since 2003.
Deepti is the lead clinician for the systemic mastocytosis and chronic myeloid leukaemia services. The ECNM UK mastocytosis centre of excellence at Guys and St Thomas Hospitals was jointly established by Deepti and Dr Clive Grattan in 2005. This nationally recognised service accepts referrals from across the UK, Ireland and further afield.
She is CI for landmark trials for patients with advanced/indolent systemic mastocytosis – PKC412, EXPLORER, PATHFINDER and PIONEER. She is a member of the study steering committee for the EXPLORER/PATHFINDER trials (Avapritinib in advanced SM) and APEX trial (Bezuclastinib) for patients with advanced SM.
Deepti is actively involved in the education of clinicians and patients improve understanding of mast cell disorders by delivering regular teaching in regional, national, international meetings in addition to the UKMasto.org and TMS patient support groups.

Farhad Ravandi, MD, is Janiece and Stephen A. Lasher Professor of Medicine and chief of the Section of Acute Myeloid Leukemia in the Department of Leukemia at The University of Texas MD Anderson Cancer Center (MDACC) in Houston. He graduated from the University of London, UK, and undertook residency and fellowship training at Baylor College of Medicine and MDACC. During this time, he specialized in the management of hematologic malignancies and stem cell transplantation. He then moved to the University of Illinois at Chicago as director of the leukemia program and interim director of stem cell transplant program for 3 years, until he joined the MDACC Department of Leukemia in 2003. He is board certified in internal medicine, hematology, and medical oncology.

Dr Ravandi’s main areas of interests are therapy of acute myeloid leukemia, as well as rare leukemias, including Philadelphia chromosome-positive acute lymphoblastic leukemia, hairy cell leukemia, and T-cell leukemias. He has authored several book chapters and many articles in peer-reviewed journals. He is a member of several professional societies, including the American Society of Hematology, American Society of Clinical Oncology, and Society of Hematologic Oncology, and is a member of the editorial boards of several journals including Blood, Haematologica, American Journal of Hematology, Cancer, Blood Cancer Journal, Leukemia and Lymphoma and others.

Mathias Rummel, MD, is a Professor of Medicine and is the director of the Department for Hematology at the Clinic for Hematology and Medical Oncology at the Justus-Liebig University-Hospital in Giessen, Germany.

His current research focuses on novel treatment approaches in hematological malignancies, most notably Follicular Lymphoma, Mantle Cell Lymphoma, Waldenström’s Macroglobulinemia and other indolent lymphomas as well as Chronic Lymphocytic Leukemia (CLL), Hairy Cell Leukemia and also in the non-malignant hematological disorder Immune Thrombocytopenia (ITP).

He is the chair of the large cooperative German Study group indolent Lymphomas (StiL) with more than 220 study sites in Germany and Austria and is the principal investigator of several on-going clinical protocols, in particular of Investigator Initiated Trials (IIT).

Professor Rummel is actively involved in a number of professional scientific societies, including the American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), the European Haematology Association (EHA), and the German Society of Haematology and Oncology (DGHO).

He is the principal investigator of many clinical trials in Leukemias, Lymphomas, Hairy Cell Leukemia, and Immune Thrombocytopenia (ITP), and has published several book chapters and papers in peer reviewed scientific journals.

Miguel Sanz is Researcher Emeritus of the Instituto de Investigación Sanitaria La Fe and Honorary Professor of the Department of Medicine at the University of Valencia. After earning his medical degree at the University of Salamanca in Spain, he was intern, resident and subsequently completed a fellowship in Hematology at the University Hospital La Fe. He was appointed as Head of the Clinical Hematology Section to the University Hospital La Fe in 1977 and then later promoted to Head of the Hematology Department in 2007 as well as Full Professor of Medicine at the University of Valencia. Professor Sanz is chairman of the Spanish PETHEMA Group and leads the working parties of acute myeloid leukemia and infections in neutropenic patients. He is currently a reviewer for numerous high-profile medical journals including all top hematology journals, and has authored more than 620 peer-reviewed papers, numerous book chapters, and in excess of 1100 abstracts at national and international meetings. Professor Sanz has also lectured widely in Europe, North, central and South America, as well as in Middle East and Asia, serving as lecturer at the American Society of Hematology and European Hematology Association meetings in several occasions.

Dr Phillip Scheinberg graduated in Medicine from the University of Santo Amaro, São Paulo, Brazil in 1995. He then undertook residencies in Internal Medicine at the University of São Paulo (1996–1997) and at Mount Sinai Medical Center, Florida, USA (1997–2000). From 2000 to 2001, he worked as Medical Chief Resident at Mount Sinai Medical Center.

Dr Scheinberg undertook his hematology-oncology fellowship and training at the Hematology Branch, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health from 2001 to 2006. He then remained on staff at the Hematology Branch of the NHLBI from 2006 to 2011, where he developed several clinical protocols in bone marrow failure syndromes as well as conducted laboratory research in bone marrow failure syndromes, bone marrow transplantation, cellular immunity against viral, tumoral and allogeneic antigens. He is currently Head of the Division of Hematology, Hospital A Beneficência Portuguesa, São Paulo, Brazil.

Dr Terpos main research interest is the biology and management of bone disease in multiple myeloma. He also studies the role of modern imaging (MRI, PET/CT) and of MRD in plasma cell neoplasms. In the clinical research era, Dr Terpos participates in many important clinical trials and is the PI of several studies with novel agents in the field of myeloma.

His research work was reported in more than 660 papers in peer-reviewed journals and Dr Terpos has more 30,000 citations and an h-index of 82 in ISI/Web of Knowledge and more than 44,000 citations and an h-index of 100 in Google Scholar.

Dr Terpos is co-chairing the Bone Sub-Committee of the International Myeloma Working Group and is a member of the Guideline Subgroup of the European Myeloma Network. Dr Terpos is also a member of the Education and Publication Committees of the International Myeloma Society, and he is the vice-president of the Greek Myeloma Study Group.

He has given lectures at ASH, ASCO & EHA meetings, International Myeloma Workshops and in several national meetings. He is Associate Editor of HemaSphere (official journal of EHA) and member of the Editorial Board of Blood Cancer Journal, American Journal of Hematology and Haematologica .